Abacavir pharmacokinetics during chronic therapy in HIV-1-infected adolescents and young adults by Sleasman J W, Robbins B L, Cross S J, Lindsey J C, Kraimer J M, Heckman B E, Sprenger H L, Tustin N B, Rose C H, Poston P A, Neal E F, Pakes G E, Nikanjam M, Capparelli E V in Clinical pharmacology and therapeutics (2009).

[PMID: 19118380] PubMed


The pharmacokinetics of abacavir and its metabolites were investigated in 30 human immunodeficiency virus (HIV)-infected adolescents and young adults 13-25 years of age, equally divided into two groups: <18 years of age and >or=18 years of age. All the subjects received the recommended adult dose of 300 mg twice daily. The area under the plasma concentration-time curve (AUC) and half-life of abacavir did not differ significantly between the age groups or by gender or race, and there were only modest associations of age with apparent abacavir clearance and with volume of distribution. There were no significant correlations of carboxylate or glucuronide metabolite levels with age or gender, although glucuronide AUC was higher in Hispanic subjects than in African-American subjects. Zidovudine and lamivudine concentration profiles were also similar in the two age groups. A novel aspect of the study included an assessment of intracellular carbovir, zidovudine, and lamivudine triphosphate levels, and these were found to be similar in the two age-based groups. Overall, these findings suggest that current recommendations relating to adult dosages are appropriate for adolescents and young adults.

[ hide abstract ]

Discussed In Paper


Rx Annotations

No dosing information annotated.